Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis
Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis
Treatment of painful vaso-occlusive crises, the most common manifestation of sickle cell
 disease, is notoriously limited. vaso-occlusive crises pain is multifactorial with a
 psychological component. The hypothesis is that the music therapy program MUSIC CARE® can
 help alleviate severe vaso-occlusive crises pain in synergy with traditional treatment in
 sickle cell disease patients. The main objective of this prospective, randomized, open label
 study is to test the effect of the music therapy program MUSIC CARE® on daily mean morphine
 consumption during the 3 first days of hospitalisation for severe vaso-occlusive crises.
Sickle cell disease, the most frequent monogenic disease in France and in the world, is
 induced by a mutation in the β-globin chain of hemoglobin with production of hemoglobin S.
 The course of the disease is characterized by very painful, for which treatment is
 notoriously limited. vaso-occlusive crises pain is multifactorial with biological and
 psychological components. A few studies suggest a beneficial effect of relaxation techniques
 in the management of Sickle cell disease pain. MUSIC CARE® is a novative music therapy
 program which proved efficient in different models of acute or chronic pain. the hypothesis
 is that this program can help alleviate severe pain in synergy with traditional treatment in
 SS Sickle cell disease patients, via a dual biological and psychological effect. The main
 objective of this prospective, randomized, open label study is to test the effect of the
 music therapy program MUSIC CARE® on daily mean morphine consumption during the 3 first days
 of hospitalisation for severe vaso-occlusive crises in adult SS Sickle cell disease patients.
 Secondary outcomes will include mean daily Visual Analogic Scale during the first 3 days of
 hospitalization for severe vaso-occlusive crises, acute complications of vaso-occlusive
 crises, duration of severe vaso-occlusive crises and of hospitalization, Hospital Anxiety and
 Depression Scale.

 20 patients will be included in each group for this pilot study.
Inclusion Criteria:

 -  Age>18 years

 -  patients with homozygous Sickle Cell Disease (HbSS,or HbSß0) confirmed by laboratory
 center

 -  hospitalized for severe vaso-occlusive crisis

 -  Visual Analogic Scale≥6 at entry

 -  able to speak and write French

 -  Patient in physical and clinical capacity of consent (signature of the informed
 consent of the patient or in the presence of a third party)

 -  affiliated to a social insurance; not subject to a legal protection

 Exclusion Criteria:

 -  other hemoglobinopathy

 -  pregnancy or post-scriptum (40 days after labor)

 -  antecedent of Reflex Epilepsies

 -  major hypoacusia

 -  Patients already engaged in a therapeutic protocol or in the period of exclusion after
 a previous interventional research.